KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin
about
The Significance of Ras Activity in Pancreatic Cancer InitiationGenetics and biology of pancreatic ductal adenocarcinomaDevelopmental Pathways Direct Pancreatic Cancer Initiation from Its Cellular OriginGenetically engineered mouse models of pancreatic adenocarcinomaHuman correlates of provocative questions in pancreatic pathologyMet receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancerSomatic mutations in exocrine pancreatic tumors: association with patient survivalA Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the PancreasClinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimensPathology and molecular genetics of pancreatic neoplasms.Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer.Absence of pancreatic intraepithelial neoplasia predicts poor survival after resection of pancreatic cancer.Detection of early-stage pancreatic adenocarcinoma.Mutational analysis of cytocentrifugation supernatant fluid from pancreatic solid mass lesions.Precursor lesions of early onset pancreatic cancer.Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias.The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center.Cellular features of senescence during the evolution of human and murine ductal pancreatic cancerRAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.Pancreatic cancer genomes: toward molecular subtyping and novel approaches to diagnosis and therapy.A Review of the Current Status and Concept of the Emerging Implications of Zinc and Zinc Transporters in the Development of Pancreatic Cancer.Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinomaAcinar cell plasticity and development of pancreatic ductal adenocarcinoma.The cytotoxic role of RREB1, ZIP3 zinc transporter, and zinc in human pancreatic adenocarcinoma.Targeting reactive oxygen species in development and progression of pancreatic cancer.Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas.Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation.Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.Modified PNA-PCR method: a convenient and accurate method to screen plasma KRAS mutations of cancer patients.STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.Disputed paternity: the uncertain ancestry of pancreatic ductal neoplasia.Metaplasia: tissue injury adaptation and a precursor to the dysplasia-cancer sequence.Genetic basis of a common tumor origin in the development of pancreatic mixed acinar-neuroendocrine-ductal carcinoma: A case report.Dissection of the Mouse Pancreas for Histological Analysis and Metabolic Profiling.Id3 modulates cellular localization of bHLH Ptf1-p48 protein.Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development.Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.Activation of protein kinase Cδ leads to increased pancreatic acinar cell dedifferentiation in the absence of MIST1.
P2860
Q26765230-014208FD-C21E-4A33-B2B8-6E143B69EB9BQ26765438-2B133937-E068-4646-9537-EF287215D311Q26774942-15D9420E-660F-4351-AB3B-CF266852985AQ27002973-C936A6CD-7C76-46EB-8EAE-8D1CCA914531Q27023576-380CDF84-9475-42DD-9FBA-E506BE74D70FQ27334957-BEF06450-EF16-46FA-8766-517200311CC0Q27852155-74F0516B-813C-46C5-97C1-F027C2799531Q28082890-7942B843-631A-4361-A150-EE92283FC74FQ30416415-75928AC7-8F5E-46B9-9768-601FC9780F43Q33581119-74FC58D0-888F-48A2-A47B-71F47EE2BEEAQ34014091-EB276845-1CA7-4D5B-B1F5-A2ACAC626F18Q34167517-C2A0B07E-6B61-4CD7-B3E3-AD68DA2A6EA2Q34293089-4260E32E-4D92-4358-8801-43F67BFA215BQ34531918-16E7B9A8-2C3C-4097-8BA5-BD3B43B40164Q34705599-73817690-35FF-4F7B-94FD-8D38C4119963Q35194027-7895F18E-5D76-4F2E-89F8-DCF428EA7A1BQ35217385-3657C85C-B752-45E5-B9F0-7CB78F6DF261Q36096239-6BFDFBB0-A80F-42F9-A3C1-86ADCB8D4034Q36398735-5B13FDC0-DA1B-4B22-85D1-A8B40F0F8201Q37259201-C7CB030F-D744-4FED-B067-BCA08A13DE13Q38113752-034E2977-2C01-4F06-9313-D237B706F638Q38160227-CC9E7147-3A02-4052-B9DB-A2C18EC5F14CQ38439880-2BC6756D-8C4A-414A-8635-8957E366CAE4Q38922230-8A3EA48A-246E-4C33-804D-A3D9A40D0354Q38972919-4B6437CE-43A1-4C4F-BBE8-582060BEAAA9Q39007517-07F2D797-EB38-43D6-934B-CA66E51D86D4Q39008039-EEECD493-1F39-48EB-9679-DF59A6F05102Q39156056-058C039E-4F39-4254-83FC-E9ACC0FBFFB1Q39337159-C25E426E-4130-4C57-8DE4-310A727D9E41Q39400627-3CFD2E40-3B73-4418-8F11-6CAD84D0AB75Q39540918-ABEB770E-8ABB-40B4-8CC6-9CDA6F4B13B0Q40034316-43BA84D5-654F-4552-A0B4-75B86FB25DADQ41845030-2A21E7A5-BB96-444A-AE7C-646F5CB0F2D0Q47786705-F13BC671-456C-4803-9BE5-2A993338531FQ50319202-38C4AE85-037A-4EE4-B511-213024F5AEC1Q51795537-E1A111AD-BC62-4DB7-AB0A-D50FBDB2EF16Q52603542-CEAF03EB-454A-4672-82ED-53C7478306B8Q52714316-0C7B09C3-B1E7-425D-8C0A-B0FCB525431CQ54271301-424305A0-FF6F-4302-B36E-8EC17D21104AQ54526478-5DA76168-6AB5-4105-B50B-3A808F48C819
P2860
KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
KRAS2 mutations in human pancr ...... ncreatic cancer cell of origin
@ast
KRAS2 mutations in human pancr ...... ncreatic cancer cell of origin
@en
type
label
KRAS2 mutations in human pancr ...... ncreatic cancer cell of origin
@ast
KRAS2 mutations in human pancr ...... ncreatic cancer cell of origin
@en
prefLabel
KRAS2 mutations in human pancr ...... ncreatic cancer cell of origin
@ast
KRAS2 mutations in human pancr ...... ncreatic cancer cell of origin
@en
P2093
P2860
P50
P1476
KRAS2 mutations in human pancr ...... ncreatic cancer cell of origin
@en
P2093
Chanjuan Shi
Hirohiko Kamiyama
James R Eshleman
Mehtab Khan
Phillip Lim
Robert A Anders
P2860
P304
P356
10.1158/1541-7786.MCR-08-0206
P577
2009-02-10T00:00:00Z